Home » Stocks » ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Stock Price: $181.83 USD -0.27 (-0.15%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 21.23B
Revenue (ttm) 570.94M
Net Income (ttm) -876.35M
Shares Out 117.08M
EPS (ttm) -7.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $181.83
Previous Close $182.10
Change ($) -0.27
Change (%) -0.15%
Day's Open 181.51
Day's Range 180.18 - 184.45
Day's Volume 345,726
52-Week Range 119.29 - 184.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in primary hyperoxaluria type 1 (PH1) associated with progressive decline...

9 hours ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label ...

13 hours ago - Business Wire

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter endin...

1 week ago - Business Wire

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Other stocks mentioned: BEAM, BNTX, CRSP, EDIT, MRNA, NTLA
3 weeks ago - The Motley Fool

The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1% drop over the last five trading days, afte...

Other stocks mentioned: NTLA
4 weeks ago - Forbes

Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.

4 weeks ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 study evaluating the effi...

4 weeks ago - Business Wire

The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8th annual series of “RNAi Roundtable” w...

1 month ago - Business Wire

The stock price of Alnylam Pharmaceuticals, a relatively smaller pharmaceutical company with a market capitalization of $18 billion, has seen a 22% rise over the last twenty-one trading days, and we bel...

1 month ago - Forbes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from a Phase 3b open-label study conducted to eva...

1 month ago - Business Wire

Here's one genetics play that you might want to put on your radar.

Other stocks mentioned: NTLA, NVS, PFE, REGN
1 month ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its APOLLO-B Phase...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following co...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has started a clinical study of a biannual dosing regimen ...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following co...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-mo...

2 months ago - Business Wire

Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.

2 months ago - Zacks Investment Research

Alnylam (ALNY) delivered earnings and revenue surprises of 2.29% and 0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Marc...

3 months ago - Business Wire

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced full positive results from the HELIOS-A Phase 3 study of vutrisira...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim results from the ongoing Phase 1 study of ALN-AGT...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 20th Annual...

3 months ago - Business Wire

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). The results ...

3 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that pivotal trial results from the ILLUMINATE-A Phase 3 study of ...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 3rd ...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 9-month results from the HELIOS...

4 months ago - Business Wire

Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GSK4182136)....

4 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today issued its first Corporate Responsibility (CR) Summary, formalizing the mana...

4 months ago - Business Wire

FRISCO, Texas--(BUSINESS WIRE)-- #soleohealhtotreatAHPwithGIVLAARI--Soleo Health to Administer Alnylam Pharmaceuticals' GIVLAARI® (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following co...

5 months ago - Business Wire

With the trading day more than halfway over, the broad markets could not make up their mind on a direction.

Other stocks mentioned: FL, NVDA, PBR, PBR.A, DAL, BBIO, FREE ...
5 months ago - 24/7 Wall Street

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 10th Annual...

5 months ago - Business Wire

Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.

5 months ago - Zacks Investment Research

Alnylam (ALNY) delivered earnings and revenue surprises of -8.29% and 14.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 19.19% over the past year to ($1.60), which beat the ...

5 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full ...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and y...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the Company's p...

6 months ago - Business Wire

Alnylam announced that the HELIOS-A Phase III study of vutrisiran for hATTR-polyneuropathy achieved all of its primary and secondary endpoints. Vutrisiran's improved dosing profile and tolerability are ...

6 months ago - Seeking Alpha

Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational ...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39th Annual...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial ...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, the Compan...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Inv...

7 months ago - Business Wire

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatme... [Read more...]

Industry
Biotechnology
IPO Date
May 28, 2004
CEO
John Maraganore
Employees
1,453
Stock Exchange
NASDAQ
Ticker Symbol
ALNY
Full Company Profile

Financial Performance

In 2020, ALNY's revenue was $492.85 million, an increase of 124.28% compared to the previous year's $219.75 million. Losses were -$858.28 million, -3.14% less than in 2019.

Financial Statements

Analyst Forecasts

According to 24 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is 174.78, which is a decrease of -3.88% from the latest price.

Price Target
$174.78
(-3.88% downside)
Analyst Consensus: Buy